Live chat

Scientist I, Research

Biogen - Cambridge, MA

Primary responsibilities:

• Conducting experiments to elucidate the roles of key regulators of disease processes and converting discoveries into target validation projects .

• Designing and conducting creative screens to discover novel therapeutic targets for AD, using genetic, molecular, pharmacological and other approaches in collaboration with existing target discovery team.

• Participating in cross-functional teams to support preclinical drug discovery and development with the potential to lead projects in the early drug discovery stages

• Participating in external research collaborations

Requisition Number


Employment Category

Full-Time Regular

External Posting Title

Scientist I, Research

Job Category

Research & Development



• Strong publication record and demonstrated experience conducting independent research

• First-hand experience with fundamental as well as cutting-edge cell biology and molecular biology techniques

• Extensive experience with cell culture, primary cells and/or stem cells with a strong background in assay development

• Strong background in neurodegenerative diseases

• Experience interpreting large data sets, such as next generation sequencing or microarray data

• Track record of collaborating with other scientists

• Excellent verbal and written communication skills


• Experience with in vivo models of neurodegenerative diseases

• Strong background in Alzheimer's disease


PhD with a minimum of 3 years of experience

Experience Level

Mid-Senior Level


We seek an outstanding molecular biologist to work on multiple aspects of preclinical gene therapy for SMA and ALS within the Neuromuscular and Movement Disorders Research Unit. The position will require a demonstrated ability to interact across teams within the Research Unit as well as with scientists with complementary skill sets within other departments. The successful candidate will have hands-on expertise in AAV vectors as well as multiple modalities of RNAi. He/she should be comfortable


9 days



Scientist I, Research Biogen - Cambridge, MA, United States


Location: Cambridge, MA

Company Profile:
Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. Its marketed products include AVONEX for the treatment of relapsing multiple sclerosis (MS); TYSABRI to treat relapsing MS; RITUXAN for treating relapsed or refractory, CD20-positive, and B-cell Non-Hodgkin’s lymphoma (NHL); FUMADERM for the treatment of severe plaque psoriasis in adult patients; and FAMPYRA, an oral compound for the improvement of walking in adult patients with MS with walking disability. The company’s products that completed Phase III clinical trials comprise TECFIDERA (BG-12) for MS; Peginterferon beta-1a to prolong the effects and reduce the dosing frequency of interferon beta-1a; and long-lasting Factor VIII and IX product candidates for the treatment of hemophilia. Its products under Phase III clinical trials consist of Daclizumab, a monoclonal antibody in relapsing MS; TYSABRI for secondary progressive MS; and GA101, a monoclonal antibody for chronic lymphocytic leukemia and NHL. The company’s Phase II clinical trial products include Anti-LINGO for optic neuritis; STX-100 for idiopathic pulmonary fibrosis; and ANTI-TWAEK for lupus nephritis. The company’s Phase I clinical trial products comprise Anti-LINGO for MS; BIIB037 for Alzheimer's disease; Neublastin for neuropathic pain; and Anti-CD40 Ligand for general lupus, as well as Phase 1b/2a clinical trial product includes ISIS-SMNRx for spinal muscular atrophy. It has collaboration agreements with Genentech, Inc.; Elan Pharma International, Ltd; Acorda Therapeutics, Inc.; Portola Pharmaceuticals, Inc.; and Swedish Orphan Biovitrum AB. The company was formerly known as IDEC Pharmaceuticals Corporation and changed its name to Biogen Idec Inc. in November 2003. Biogen Idec Inc. was founded in 1985 and is headquartered in Cambridge, Massachusetts.